An artificial intelligence-based gout management system reduced chronic kidney disease incident and improved target serum urate achievement.

Journal: Rheumatology (Oxford, England)
PMID: 39504469

Abstract

OBJECTIVES: Stage ≥3 chronic kidney disease (CKD) affects ∼25% of people with gout. The effects of urate-lowering therapy (ULT) on CKD incidence and progression have remained inconclusive. Here, we assessed the impact of a gout ULT clinic intervention using artificial intelligence (AI) on CKD incidence and achievement of serum urate (SU) target.

Authors

  • Han Qi
    Shandong Provincial Clinical Research Center for Immune Diseases and Gout, Qingdao, China.
  • Jie Lu
    Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
  • Nicola Dalbeth
    University of Auckland, Auckland, New Zealand.
  • Mingshu Sun
    Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Zhen Liu
    School of Pharmacy, Fudan University, PR China; Analytical Service Unit, WuXi AppTec (Shanghai) Co., Ltd, Shanghai, 200131, PR China.
  • Xiaopeng Ji
    School of Mathematics, Physics and Computing, Centre for Health Research, University of Southern Queensland, Toowoomba, QLD, Australia.
  • Aichang Ji
    Shandong Provincial Clinical Research Center for Immune Diseases and Gout, Qingdao, China.
  • Can Wang
    School of Acu-Mox and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Wenyan Sun
    The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
  • Xinde Li
    Shandong Provincial Clinical Research Center for Immune Diseases and Gout, Qingdao, China.
  • Yuwei He
    Beijing National Research Center for Information Science and Technology (BNRist), Tsinghua University, Beijing, 100084, China.
  • Lingling Cui
    The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
  • Lin Han
    Department of Radiology Center, The First Affiliated Hospital of Xinxiang Medical University, Xin Xiang, China.
  • Ying Chen
    Department of Endocrinology and Metabolism, Fudan Institute of Metabolic Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Fei Yan
    Department of Infectious Diseases, Affiliated Taizhou Hospital of Wenzhou Medical University, No.50 Ximeng Road, Taizhou, 317000, China.
  • Yi Zhang
    Department of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Jilin University, Changchun, China.
  • Robert Terkeltaub
    VA San Diego VA Healthcare Center, University of California San Diego, San Diego, CA USA.
  • Changgui Li
    The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China lichanggui@medmail.com.cn hbchen@tongji.edu.cn huiyoyin@cityu.edu.hk.

Keywords

External Resources

Popular Topics
Recent Journals